clinical trial · NCT05787574
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Primary Immune Regulatory DisorderAutoimmune LymphoproliferativeImmune System DiseasesEmapalumabFludarabine and DexamethasoneStem Cell Transplant
brief summary
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells. "Funding Source - FDA OOPD"
started
Mar 15, 2023
primary completion
Mar 1, 2027
completion
Mar 1, 2027
last updated
Oct 29, 2025
official title
Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol